Rigel Pharmaceuticals, Inc.

RIGL· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$50.46-1.66%

2026-11-02

Financials

Valuation Metrics

Rigel Pharmaceuticals, Inc.'s Market Cap is $934M. At end of 2025 it was $770M. Ranked #2439 of 3,118 in US market (top 78%), #997 of 1,474 on NASDAQ (top 68%), #181 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$934M	US#2,439/3,118 Sec#181/265
Revenue	$277M	US#2,458/3,118 Sec#100/265
Net Income	$322M	US#1,054/3,118 Sec#35/265
Total Assets	$521M	US#2,744/3,118 Sec#160/265
Net Assets	$425M	US#2,321/3,118 Sec#125/265
Value
P/E	2.90x	US#22/3,118 Sec#2/265
P/B	2.19x	US#1,416/3,118 Sec#71/265
PEG	0.01x	US#41/3,118 Sec#5/265
P/S	3.37x	US#1,905/3,118 Sec#59/265
EV/EBITDA	9.71x	US#797/3,118 Sec#24/265
FCF Yield	8.50%	US#787/3,118 Sec#23/265
Profitability
ROE	75.67%	US#57/3,118 Sec#3/265
ROA	61.78%	US#5/3,118 Sec#1/265
Op. Margin	31.45%	US#473/3,118 Sec#25/265
Revenue Growth	3.31%	US#1,929/3,118 Sec#120/265
Earnings Growth	229.08%	US#146/3,118 Sec#8/265
Financial Health
Debt Ratio	22.43%	US#250/3,118 Sec#84/265
Total Debt	$40M	US#2,632/3,118 Sec#161/265
FCF	$79M	US#1,822/3,118 Sec#66/265
Cash	$61M	US#2,492/3,118 Sec#215/265
Current Ratio	1.95x	US#1,265/3,118 Sec#221/265
Net Debt/EBITDA	-0.22x	US#491/3,118 Sec#26/265
Performance
1Y Return	59.78%	US#359/3,118 Sec#64/265
1M Return	7.02%	US#1,086/3,118 Sec#69/265
From 52W High	-4.09%	US#151/3,118 Sec#15/265
1Y MDD	-50.08%	US#2,398/3,118 Sec#163/265
Trading
Volume	108,792 shares	US#2,837/3,118 Sec#260/265
Trading Value	$6M	US#2,537/3,118 Sec#201/265
Per Share
EPS	$17.40	US#116/3,118 Sec#4/265
BPS	$22.99	US#1,109/3,118 Sec#22/265